MedPal AI (MPAL) has published an operational update outlining how its UK platform now links the MedPal app with an artificial intelligence (AI) triage system, human-validated prescribing, and robotic pharmacy dispensing and delivery.
The company said the model is designed to generate revenue at multiple points in the patient journey, including app subscriptions priced at £3.99 per month or £29.99 per year, National Health Service (NHS) dispensing fees of £9.90+ per item, private prescription income and clinical consultation fees.
In addition, MedPal AI highlighted a range of customer acquisition channels, including NHS contracts and Distance Selling Pharmacy (DSP) licences, direct advertising through MedPal.clinic and the app, and an Epassi partnership which it said provides access to more than eleven million employees.
The company also pointed to a bi-directional cross-sell strategy, where app users are converted into pharmacy patients and pharmacy patients into app subscribers.
Meanwhile, MedPal AI said it dispensed 36,951 prescription items in January 2026 and recorded 7,791 app installs, with all installs described as paid or on an Epassi-linked acquisition pathway, with no free tier.
MedPal AI’s CEO Jason Drummond said: “MedPal AI's platform uniquely integrates AI, clinicians, and robotic dispensing for end-to-end care and revenue at every step. Diverse channels-from NHS contracts to Epassi's 11m+ employees fuel resilient growth. Our cross-sell flywheel compounds value: app users become pharmacy patients, and vice versa. With 36,951 items dispensed in January and 7,791 app installs, we are well positioned for sustained expansion.”
View from Vox
MedPal AI is leaning into a “platform” story here, with the pharmacy and prescribing layer intended to turn demand into measurable throughput and cash generation, rather than relying on app usage alone. In addition, the mix of acquisition routes - NHS volume, private marketing and the Epassi funnel - looks designed to smooth growth and reduce reliance on any single channel. The key next step is evidence that the cross-sell loop is consistently lifting subscription conversion, repeat prescribing and average revenue per patient as scale builds.